5 Stocks Pushing The Drugs Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average (^DJI) trading up 40 points (0.3%) at 12,582 as of Friday, Nov. 16, 2012, 11:59 AM ET. The NYSE advances/declines ratio sits at 1,549 issues advancing vs. 1,392 declining with 99 unchanged.

The Drugs industry currently sits down 0.7% versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Eli Lilly and Company (LLY), up 0.9%. Top gainers within the industry include Regeneron Pharmaceuticals (REGN), up 7.8%, Gilead (GILD), up 1.5% and Bristol-Myers Squibb Company (BMY), up 1.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Dynavax Technologies Corporation (DVAX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Dynavax Technologies Corporation is down $2.27 (-49.0%) to $2.36 on heavy volume Thus far, 23.3 million shares of Dynavax Technologies Corporation exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $2.22-$2.51 after having opened the day at $2.30 as compared to the previous trading day's close of $4.63.

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Dynavax Technologies Corporation has a market cap of $827.4 million and is part of the health care sector. The company has a P/E ratio of -14.5, below the S&P 500 P/E ratio of 17.7. Shares are up 39.5% year to date as of the close of trading on Thursday. Currently there are 4 analysts that rate Dynavax Technologies Corporation a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Dynavax Technologies Corporation as a sell. Among the areas we feel are negative, one of the most important has been unimpressive growth in net income over time. Get the full Dynavax Technologies Corporation Ratings Report now.

1 2 3 4 5 Next › Last »

 

For more information on AstraZeneca PLC click any of the following:

• AstraZeneca PLC Stock Price

• AstraZeneca PLC Analyst Ratings

• AstraZeneca PLC Key Stats & Profile

• AstraZeneca PLC Earnings

• AstraZeneca PLC Ratio Comparison

• AstraZeneca PLC Growth Rates

• AstraZeneca PLC Balance Sheet

• AstraZeneca PLC Cash Flow

• AstraZeneca PLC Income Statement